Sodium-glucose cotransporter (SGLT2) is not expressed in the heart but SGLT2 inhibitors are recommended by the latest treatment guidelines in patients with heart failure, with or without diabetes mellitus. Here, SLC5A2 is linked to diabetes mellitus.